Panobinostat side effects

Panobinostat (Panobinostat), as a histone deacetylase inhibitor, has shown significant efficacy in the treatment of multiple myeloma and other cancers, but its use is also accompanied by a series of potential side effects. The possible side effects of panobinostat will be described in detail below so that patients can fully understand when receiving treatment and work closely with their doctors to minimize these adverse reactions.

1. Hematological toxicity

The use of panobinostat has been associated with hematologic toxicities, including:

Anemia (Anemia): It may cause a decrease in hemoglobin levels and cause symptoms such as fatigue and weakness.

Thrombocytopenia: can reduce platelets and increase the risk of bleeding and congestion.

Leukopenia: May cause a decrease in white blood cells and affect immune system function.

These adverse reactions require regular blood monitoring during treatment and adjustment of drug dosage based on monitoring results.

2. Cardiotoxicity

The use of panobinostat may cause cardiotoxicity, manifested as:

Arrhythmias: May cause irregular heartbeats and require regular monitoring of electrocardiogram and heart function.

Patients should pay close attention to any heart-related symptoms while taking the medication and report them to their doctor in a timely manner.

3. Gastrointestinal reactions

Pabinostat may cause gastrointestinal symptoms, including:

NauseaNausea): May cause loss of appetite and dizziness.

Vomiting: May occur early in treatment.

Patients should inform their doctor about the occurrence of these symptoms so that appropriate symptomatic treatment can be taken.

4. Fatigue

During treatment, some patients may experience feelings of fatigue, which may affect their daily activities. When feeling fatigued, patients should get adequate rest and discuss possible adjustments with their doctor if necessary.

5. Other possible adverse reactions

In addition to the main side effects mentioned above, the use of panobinostat may also cause other uncomfortable symptoms, including:

Headache (Headache): May be part of treatment, but you should report it to your doctor if symptoms persist or worsen.

Weight Loss: May be related to loss of appetite, nausea, etc., affecting the patient's overall health.

6. Notes and Warnings

Patients and doctors should pay attention to the following when using panobinostat:

Cardiac monitoring: Due to the possibility of cardiotoxicity, patients need regular cardiac monitoring during treatment to ensure the stability of cardiac function.

Blood monitoring: Perform regular blood monitoring to assess the patient's platelet, white blood cell, and red blood cell levels, and to detect and deal with any abnormalities in a timely manner.

Symptomatic treatment: In response to the side effects that occur, appropriate symptomatic treatment measures are taken to improve the patient's quality of life.

7. Contraindications

Pabinostat is contraindicated in the following circumstances:

Patients who are allergic to panobinostat or any ingredient in this medicine.

Pregnant and breastfeeding women.

8. Drug interactions

When using panobinostat, careful consideration should be given to interactions with other drugs, especially drugs that may affect heart function or the blood system. Before receiving treatment, patients should give their doctor a detailed report of all medications they are currently taking, including over-the-counter medications and supplements.

9. Drug use for special groups

Children and adolescents: Data are limited, medication should be used with caution, and decisions should be made carefully based on the patient's specific situation.

Elderly patients: Because elderly patients may be more susceptible to adverse reactions, the risks and benefits need to be carefully weighed when using the drug, and dosage adjustments may be necessary.

During treatment, communication between patient and doctor is crucial. Patients should follow up regularly with their doctors and report any new or worsening symptoms to their doctors so that treatment plans can be adjusted in a timely manner. In addition, patients should also follow their doctors' recommendations and participate in necessary monitoring and examinations to ensure that the use of panobinostat maximizes efficacy while minimizing potential adverse reactions.

Panobinostat is not currently on the market in China, so patients cannot purchase it domestically and need to purchase panobinostat through overseas channels. There are only panobinostat original drugs available abroad, mainly the European version of the Swiss Novartis original drug, which is expensive, as high as more than 40,000 yuan.